A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 26, Issue 9, 2011, Pages 937-943

  Devanand, D P ^a,b   Pelton, Gregory H ^a,b   Cunqueiro, Karine ^a   Sackeim, Harold A ^a   Marder, Karen ^a,b  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Alzheimer's disease; antipsychotic; discontinuation

Indexed keywords

HALOPERIDOL; PLACEBO;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ETHNICITY; HUMAN; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; TARDIVE DYSKINESIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RECURRENCE; RISK;

EID: 79951816345     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2630     Document Type: Article

References (37)

1. Ballard C, Brown R, Fossey J, et al,. 2009a. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (The CALM-AD trial). Am J Geriatr Psychiatry 17 (9): 726-733.
2. Ballard C, Hanney ML, Theodoulou M, et al,. DART-AD investigators. 2009b. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8 (2): 151-157.
3. Ballard C, Margallo Lana M, Theodoulou M, et al,. 2008. A randomised, blinded, placebo-controlled trial in dementia patients continuing to take or discontinued from treatment with neuroleptics (the DARTAD trial). PLoS Med 5: e76.
4. Ballard CG, Thomas A, Fossey J, et al,. 2004. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 65: 114-119.
5. Blessed G, Tomlinson BE, Roth M,. 1968. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114: 797-811.
6. Bridges-Parlet S, Knopman D, Steffes S,. 1997. Withdrawal of neuroleptic medications from institutionalised dementia patients, results of a doubleblind baseline-treatment-controlled pilot study. J Geriatric Psychiatry Neurol 10: 119-126. (Pubitemid 27478613)
7. Chui HC, Lyness SA, Sobel E, et al,. 1994. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 51 (7): 676-681. (Pubitemid 24201886)
8. Cohen-Mansfield J, Lipson S, Werner P, et al,. 1999. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 159 (15): 1733-1740. (Pubitemid 29379136)
9. DeDeyn PP, Rabheru K, Rasmussen A, et al,. 1999. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53: 946-955. (Pubitemid 29442108)
10. Devanand DP, Jacobs DM, Tang M-X, et al,. 1997. The course of psychopathologic symptoms in mild to moderate Alzheimer's disease. Arch Gen Psychiatry 54: 257-263. (Pubitemid 27132054)
11. Devanand DP, Marder K, Michaels KS, et al,. 1998. A randomized, placebo-controlled, dose-comparison trial of haloperidol treatment for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 155: 1512-1520. (Pubitemid 28512018)
12. Devanand D, Miller L, Richards M, et al,. 1992. The Columbia University Scale for psychopathology in Alzheimer's disease. Arch Neurol 49: 371-376.
13. Fahn S, Marsden CD, Calne D,. 1987. Recent Developments in Parkinson's Disease. Macmillan Healthcare Information: Florham Park, NJ.
14. Finkel SI, Costa e, Silva J, et al,. 1996. Behavioral and psychological signs and symptoms of dementia: a consensus statement of current knowledge and implications for research and treatment. Int Psychogeriatr 8 (Suppl 3): 497-500. (Pubitemid 27229556)
15. Fitz D, Mallya A,. 1992. Discontinuation of a psychogeriatric program for nursing home residents: psychotropic medication changes and behavioral reactions. J Appl Gerontol 11 (1): 50-63.
16. Folstein MF, Folstein SE, McHugh PR,. 1975. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
17. Holm A, Michel M, Stern GA, et al,. 1999. The outcomes of an inpatient treatment program for geriatric patients with dementia and dysfunctional behaviors. Gerontologist 39 (6): 668-676. (Pubitemid 30058541)
18. Horwitz GJ, Tariot PN, Mead K, Cox C,. 1995. Discontinuation of antipsychotics in nursing home patients with dementia. Am J Geriatr Psychiatry 3: 290-299.
19. Katz I, de Deyn PP, Mintzer J, et al,. 2007. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry 22 (5): 475-484. (Pubitemid 46831692)
20. Katz IR, Jeste DV, Mintzer JE, et al,. 1999. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 60: 107-115. (Pubitemid 29104387)
21. Kong EH, Evans LK, Guevara JP,. 2009. Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis. Aging Ment Health 13: 512-520.
22. Lyketsos CG, Steinberg M, Tschanz JT, et al,. 2000. Mental and behavioral disturbances in dementia: findings from the cache county study on Memory in Aging. Am J Psychiatry 157: 708-714. (Pubitemid 30249648)
23. McKhann G, Drachman D, Folstein M,. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944. (Pubitemid 14076461)
24. Raivio MM, Laurie JV, Strandberg TE, et al,. 2007. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry 15: 416-424.
25. Rovner BW, Steele CD, Shmuely Y, Folstein MF,. 1996. A randomized trial of dementia care in nursing homes. J Am Geriatr Soc 44 (1): 7-13. (Pubitemid 26017760)
26. Scarmeas N, Brandt J, Blacker D, et al,. 2007. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol 64 (12): 1755-1761. (Pubitemid 350254938)
27. Schneider LS, Dagerman KS, Insel P,. 2005. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294: 1934-1943. (Pubitemid 41464695)
28. Schneider LS, Dagerman K, Insel PS,. 2006a. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14: 191-210.
29. Schneider LS, Tariot PN, Dagerman KS, et al,. 2006b. CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355: 1525-1538. (Pubitemid 44547805)
30. Simoni-Wastila L, Ryder PT, Qian J, et al,. 2009. Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 17: 417-427.
31. Simpson GM, Lee JH, Zoubok B, et al,. 1979. A rating scale for tardive dyskinesia. Psychopharmacology 64: 171-179. (Pubitemid 9227085)
32. Stern Y, Mayeux R, Hesdorfer D, Sano M,. 1990. Measurement and prediction of functional change in Alzheimer's disease. Neurology 40: 8-14. (Pubitemid 20032883)
33. Street JW, Clark WS, Gannon KS, et al,. 2000. Olanzapine treatment of psychotic and behavioral symptoms in patients with alzheimer disease in nursing care facilities. Arch Gen Psychiatry 57: 2269-2276.
34. Suh GH, Shah A,. 2005. Effects of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr 17: 429-441. (Pubitemid 41391687)
35. Sultzer DL, Davis SM, Tariot PN, et al,. CATIE-AD Study Group. 2008. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165 (7): 844-854. (Pubitemid 351948716)
36. Tariot PN, Mack JL, Patterson MB, et al,. 1995. The behavior rating scale for dementia (BRSD) of the consortium to establish a registry for Alzheimer's disease (CERAD). Am J Psychiatry 152: 1349-1357.
37. Thapa PB, Meador KG, Gideon P, Fought RL, Ray WA,. 1994. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc 42 (3): 280-286. (Pubitemid 24079870)